CN118974060A - 用于治疗疾病的利福布汀类似物 - Google Patents

用于治疗疾病的利福布汀类似物 Download PDF

Info

Publication number
CN118974060A
CN118974060A CN202380032448.9A CN202380032448A CN118974060A CN 118974060 A CN118974060 A CN 118974060A CN 202380032448 A CN202380032448 A CN 202380032448A CN 118974060 A CN118974060 A CN 118974060A
Authority
CN
China
Prior art keywords
alkyl
optionally substituted
independently
aryl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032448.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·安特雷格
M·布罗特
G·E·戴尔
O·德费尔
M·吉青格
S·洛丘罗
M·曼戈
V·特雷博斯克
N·威兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CN118974060A publication Critical patent/CN118974060A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380032448.9A 2022-04-11 2023-04-06 用于治疗疾病的利福布汀类似物 Pending CN118974060A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22167670 2022-04-11
EP22167670.3 2022-04-11
PCT/EP2023/059154 WO2023198597A1 (en) 2022-04-11 2023-04-06 Rifabutin analogs for the treatment of disease

Publications (1)

Publication Number Publication Date
CN118974060A true CN118974060A (zh) 2024-11-15

Family

ID=81306910

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032448.9A Pending CN118974060A (zh) 2022-04-11 2023-04-06 用于治疗疾病的利福布汀类似物

Country Status (7)

Country Link
US (1) US20250235434A1 (enExample)
EP (1) EP4508053A1 (enExample)
JP (1) JP2025513019A (enExample)
CN (1) CN118974060A (enExample)
AU (1) AU2023251806A1 (enExample)
CA (1) CA3253889A1 (enExample)
WO (1) WO2023198597A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132358A1 (en) * 2023-12-21 2025-06-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
EP4696694A1 (en) 2024-08-14 2026-02-18 BioVersys AG Antibiotic rifabutin analogs
EP4696695A1 (en) * 2024-08-14 2026-02-18 BioVersys AG Antibiotic rifabutin analogs
WO2026062070A1 (en) * 2024-09-18 2026-03-26 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of infectious diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
PT102807A (pt) 2002-07-09 2004-01-30 Inst Nac De Engenharia E Tecno Derivados n-substituidos de rifabutina uteis como agentes antimicrobianos, processo para a sua preparacao e sua utilizacao como medicamentos

Also Published As

Publication number Publication date
EP4508053A1 (en) 2025-02-19
JP2025513019A (ja) 2025-04-22
WO2023198597A1 (en) 2023-10-19
CA3253889A1 (en) 2023-10-19
US20250235434A1 (en) 2025-07-24
AU2023251806A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
CN118974060A (zh) 用于治疗疾病的利福布汀类似物
EP3571189B1 (en) Pyridine compounds as allosteric shp2 inhibitors
US10555935B2 (en) 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2024165591A1 (en) Rifabutin analogs for the treatment of bacterial diseases
CN119998299A (zh) 用于治疗疾病的利福布汀类似物
CN118843633A (zh) 用于治疗疾病的利福布汀类似物
CA3202516A1 (en) Aminothiazole compounds as c-kit inhibitors
CN119522216A (zh) Ptpn2抑制剂
EP4469463B1 (en) Rifamycin derivatives for the treatment of diseases
WO2026037898A1 (en) Antibiotic rifabutin analogs
EP4696694A1 (en) Antibiotic rifabutin analogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination